Precision oncology for biliary tract tumors: it's written in blood!

Affiliations

¹ Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston.
² Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston; MD Anderson Cancer Network, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: vsubbiah@mdanderson.org.

Free article

Editorial

M A Gouda et al. Ann Oncol. 2022 Dec.

Free article

. 2022 Dec;33(12):1209-1211.

doi: 10.1016/j.annonc.2022.09.157. Epub 2022 Sep 28.

¹ Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston.
² Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston; MD Anderson Cancer Network, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: vsubbiah@mdanderson.org.

No abstract available

Comment on

The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer.
Berchuck JE, Facchinetti F, DiToro DF, Baiev I, Majeed U, Reyes S, Chen C, Zhang K, Sharman R, Uson Junior PLS, Maurer J, Shroff RT, Pritchard CC, Wu MJ, Catenacci DVT, Javle M, Friboulet L, Hollebecque A, Bardeesy N, Zhu AX, Lennerz JK, Tan B, Borad M, Parikh AR, Kiedrowski LA, Kelley RK, Mody K, Juric D, Goyal L. Berchuck JE, et al. Ann Oncol. 2022 Dec;33(12):1269-1283. doi: 10.1016/j.annonc.2022.09.150. Epub 2022 Sep 9. Ann Oncol. 2022. PMID: 36089135